KKR & Co. Inc. logo

KKR & Co. Inc. (KKR)

Market Closed
16 Oct, 08:00 PM
NYSE NYSE
$
86. 21
-1.42
-1.6204%
$
78.26B Market Cap
30.59 P/E Ratio
0.11% Div Yield
7.46M Volume
3.39 Eps
$ 87.63
Previous Close
Add Transaction
Day Range
86.03 89.57
Year Range
82.67 144.84
Want to track KKR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
FS KKR Capital: Weak Q1 Earnings As Dividend Support Weakens

FS KKR Capital: Weak Q1 Earnings As Dividend Support Weakens

FSK offers a high 13.4% dividend yield, but dividend coverage is barely adequate and NAV continues to decline, raising sustainability concerns. Despite a strong quarter for new investments, persistent non-accruals and weak earnings suggest fundamental issues remain unresolved. FSK trades at a 10.5% discount to NAV, but this is less attractive than its historical average, reflecting market skepticism about quality.

Seekingalpha | 1 year ago
FS KKR Capital: A High-Yielding BDC Underdog

FS KKR Capital: A High-Yielding BDC Underdog

FS KKR Capital's met EPS expectations due to new investments. The BDC grew its portfolio and slightly improved its balance sheet quality, with the non-accrual percentage falling to 2.1%, based on fair value. The Company generated net investment income of $0.67 per share, fully supporting the $0.64 per share regular quarterly dividend.

Seekingalpha | 1 year ago
KKR & Co. Inc. (KKR) Q1 2025 Earnings Call Transcript

KKR & Co. Inc. (KKR) Q1 2025 Earnings Call Transcript

KKR & Co. Inc. (NYSE:KKR ) Q1 2025 Earnings Conference Call May 1, 2025 9:00 AM ET Company Participants Craig Larson - Partner and Head of Investor Relations Scott Nuttall - Co-Chief Executive Officer Robert Lewin - Chief Financial Officer Conference Call Participants Craig Siegenthaler - Bank of America Alexander Blostein - Goldman Sachs Benjamin Budish - Barclays Capital Glenn Schorr - Evercore ISI Steve Chubak - Wolfe Research Mike Brown - Wells Fargo Dan Fannon - Jefferies Patrick Davitt - Autonomous Research Arnaud Giblat - BNP Paribas Brian Bedell - Deutsche Bank Michael Cyprys - Morgan Stanley Kyle Voigt - KBW Operator Ladies and gentlemen, thank you for standing by. Welcome to KKR's First Quarter 2025 Earnings Conference Call.

Seekingalpha | 1 year ago
KKR & Co. (KKR) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

KKR & Co. (KKR) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for KKR & Co. (KKR) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 1 year ago
KKR Gains on Q1 Earnings Beat as Revenues & AUM Rise, Expenses Up Y/Y

KKR Gains on Q1 Earnings Beat as Revenues & AUM Rise, Expenses Up Y/Y

Higher revenues and solid growth in AUM balance support KKR & Co.???s Q1 earnings, while a rise in expenses acts as a spoilsport.

Zacks | 1 year ago
Unveiling KKR & Co. (KKR) Q1 Outlook: Wall Street Estimates for Key Metrics

Unveiling KKR & Co. (KKR) Q1 Outlook: Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of KKR & Co. (KKR) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks | 1 year ago
KKR Q1 Preview: A Solid Business, But Sentiment Needs To Catch Up

KKR Q1 Preview: A Solid Business, But Sentiment Needs To Catch Up

KKR & Co. Inc. is set to report Q1 results on May 1, with low expectations but the potential for a positive surprise, especially after a strong last quarter. The $1.2 billion acquisition of Biotage signals KKR's strategic expansion in life sciences, reinforcing confidence in long-term value despite market challenges. Despite a high valuation and recent stock underperformance, KKR's fundamentals remain strong, with robust cash generation, fundraising momentum, and growing assets under management.

Seekingalpha | 1 year ago
KKR Launches $1.2 Billion Takeover Bid For Swedish Life-Sciences Company Biotage

KKR Launches $1.2 Billion Takeover Bid For Swedish Life-Sciences Company Biotage

The deal values the Swedish company at $1.2 billion, and the Biotage board recommended that shareholders accept the offer.

Wsj | 1 year ago
FS KKR Capital: Buy The Tariff Tantrum, Secure A 13.7% Yield

FS KKR Capital: Buy The Tariff Tantrum, Secure A 13.7% Yield

FS KKR Capital's stock is undervalued, trading at a 21% discount to NAV, presenting a compelling buying opportunity despite higher-than-average non-accruals and declining net investment income. The BDC's credit profile has improved compared to 2023, and it could suspend its supplemental dividend to maintain its base dividend. FS KKR Capital's net investment income fell in 4Q24 due to higher loan repayments, leading to a higher dividend pay-out ratio and potential short-term dividend coverage challenges.

Seekingalpha | 1 year ago
FS KKR Capital: How Good Is This 15% Yield?

FS KKR Capital: How Good Is This 15% Yield?

FS KKR Capital offers a high dividend yield of 15%, with shares trading at an inexpensive valuation, making it an attractive entry point. Despite a 12% decline in net investment income per share, the yield on debt investments remains high, stabilizing with current interest rates. The portfolio has become more diversified, but the non-accrual rate has risen to 2.2%, indicating potential risks.

Seekingalpha | 1 year ago
KKR's "White Knight" Strategy in Buying Assets

KKR's "White Knight" Strategy in Buying Assets

Henry McVey, KKR's Head of Global Macro and Asset Allocation joined Wall Street Beat on Bloomberg Open Interest to talk about KKR's activism strategy. -------- More on Bloomberg Television and Markets Like this video?

Youtube | 1 year ago
Buyout firm KKR to buy OSTTRA in $3.1 billion deal

Buyout firm KKR to buy OSTTRA in $3.1 billion deal

Private equity firm KKR will buy post-trade services company OSTTRA in a $3.1 billion deal, S&P Global and CME Group announced on Monday.

Reuters | 1 year ago
Loading...
Load More